Liver iron is a surrogate marker of severe fibrosis in chronic hepatitis C

Journal of Hepatology

Volumn 46, Issue 4, 2007, Pages 587-595

  Guyader, Dominique ^a   Thirouard, Anne Sophie ^a   Erdtmann, Lars ^a   Rakba, Nafissa ^a   Jacquelinet, Sylvie ^a   Danielou, Hélène ^a   Perrin, Michèle ^a   Jouanolle, Anne Marie ^a   Brissot, Pierre ^a   Deugnier, Yves ^a  

^a UNIVERSITÉ DE RENNES 1   (France)

Author keywords

Chronic hepatitis C; Ferritin; Fibrosis; Iron; Liver iron; Metabolic syndrome; Steatosis

Indexed keywords

IRON;

ADULT; AGE DISTRIBUTION; ALCOHOL CONSUMPTION; ARTICLE; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HEPATITIS C; HUMAN; HYPERFERRITINEMIA; IMMUNOHISTOCHEMISTRY; IRON OVERLOAD; LIVER; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; SEX RATIO;

ADULT; AGING; ALCOHOL DRINKING; BIOLOGICAL MARKERS; FEMALE; FERRITINS; HEPATITIS C, CHRONIC; HUMANS; IRON; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SEX FACTORS;

EID: 33947103479     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2006.09.021     Document Type: Article

References (35)

1. Bonkovsky H.L., Banner B.F., and Rothman A.L. Iron and chronic viral hepatitis. Hepatology 25 (1997) 759-768
2. Pietrangelo A. Hemochromatosis gene modifies course of hepatitis C viral infection. Gastroenterology 124 (2003) 1509-1523
3. Bassett S.E., Di Bisceglie A.M., Bacon B.R., Sharp R.M., Govindarajan S., Hubbard G.B., et al. Effects of iron loading on pathogenicity in hepatitis C virus-infected chimpanzees. Hepatology 29 (1999) 1884-1892
4. Bacon B.R., and Britton R.S. The pathology of hepatic iron overload: a free radical-mediated process?. Hepatology 11 (1990) 127-137
5. Bonkovsky H.L., Troy N., McNeal K., Banner B.F., Sharma A., Obando J., et al. Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C. J Hepatol 37 (2002) 848-854
6. Erhardt A., Maschner-Olberg A., Mellenthin C., Kappert G., Adams O., Donner A., et al. HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis. J Hepatol 38 (2003) 335-342
7. Hezode C., Cazeneuve C., Coue O., Roudot-Thoraval F., Lonjon I., Bastie A., et al. Liver iron accumulation in patients with chronic active hepatitis C: prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions. J Hepatol 31 (1999) 979-984
8. Beinker N.K., Voigt M.D., Arendse M., Smit J., Stander I.A., and Kirsch R.E. Threshold effect of liver iron content on hepatic inflammation and fibrosis in hepatitis B and C. J Hepatol 25 (1996) 633-638
9. Negro F., Samii K., Rubbia-Brandt L., Quadri R., Male P.J., Zarski J.P., et al. Hemochromatosis gene mutations in chronic hepatitis C patients with and without liver siderosis. J Med Virol 60 (2000) 21-27
10. Piperno A., Vergani A., Malosio I., Parma L., Fossati L., Ricci A., et al. Hepatic iron overload in patients with chronic viral hepatitis: role of HFE gene mutations. Hepatology 28 (1998) 1105-1109
11. Lebray P., Zylberberg H., Hue S., Poulet B., Carnot F., Martin S., et al. Influence of HFE gene polymorphism on the progression and treatment of chronic hepatitis C. J Viral Hepat 11 (2004) 175-182
12. Thorburn D., Curry G., Spooner R., Spence E., Oien K., Halls D., et al. The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C. Gut 50 (2002) 248-252
13. Bataller R., North K.E., and Brenner D.A. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 37 (2003) 493-503
14. Poynard T., Yuen M.F., Ratziu V., and Lai C.L. Viral hepatitis C. Lancet 362 (2003) 2095-2100
15. Custer E.M., Finch C.A., Sobel R.E., and Zettner A. Population norms for serum ferritin. J Lab Clin Med 126 (1995) 88-94
16. Tavill A.S., and Qadri A.M. Alcohol and iron. Semin Liver Dis 24 (2004) 317-325
17. Mendler M.H., Turlin B., Moirand R., Jouanolle A.M., Sapey T., Guyader D., et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 117 (1999) 1155-1163
18. Younossi Z.M., Gramlich T., Bacon B.R., Matteoni C.A., Boparai N., O'Neill R., et al. Hepatic iron and nonalcoholic fatty liver disease. Hepatology 30 (1999) 847-850
19. Bugianesi E., Manzini P., D'Antico S., Vanni E., Longo F., Leone N., et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 39 (2004) 179-187
20. Chitturi S., Weltman M., Farrell G.C., McDonald D., Kench J., Liddle C., et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 36 (2002) 142-149
21. Corengia C., Galimberti S., Bovo G., Vergani A., Arosio C., Mariani R., et al. Iron accumulation in chronic hepatitis C: relation of hepatic iron distribution, HFE genotype, and disease course. Am J Clin Pathol 124 (2005) 846-853
22. Tung B.Y., Emond M.J., Bronner M.P., Raaka S.D., Cotler S.J., and Kowdley K.V. Hepatitis C, iron status, and disease severity: relationship with HFE mutations. Gastroenterology 124 (2003) 318-326
23. Poynard T., Bedossa P., and Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349 (1997) 825-832
24. Ryder S.D., Irving W.L., Jones D.A., Neal K.R., and Underwood J.C. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 53 (2004) 451-455
25. Bedossa P., and Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24 (1996) 289-293
26. Deugnier Y.M., Loreal O., Turlin B., Guyader D., Jouanolle H., Moirand R., et al. Liver pathology in genetic hemochromatosis: a review of 135 homozygous cases and their bioclinical correlations. Gastroenterology 102 (1992) 2050-2059
27. Ludwig J., Hashimoto E., Porayko M.K., Moyer T.P., and Baldus W.P. Hemosiderosis in cirrhosis: a study of 447 native livers. Gastroenterology 112 (1997) 882-888
28. Di Bisceglie A.M., Bacon B.R., Kleiner D.E., and Hoofnagle J.H. Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C. J Hepatol 21 (1994) 1109-1112
29. Poynard T., McHutchison J., Manns M., Trepo C., Lindsay K., Goodman Z., et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122 (2002) 1303-1313
30. Boucher E., Bourienne A., Adams P., Turlin B., Brissot P., and Deugnier Y. Liver iron concentration and distribution in chronic hepatitis C before and after interferon treatment. Gut 41 (1997) 115-120
31. Piperno A., Fargion S., D'Alba R., Roffi L., Fracanzani A.L., Vecchi L., et al. Liver damage in Italian patients with hereditary hemochromatosis is highly influenced by hepatitis B and C virus infection. J Hepatol 16 (1992) 364-368
32. Ioannou G.N., Dominitz J.A., Weiss N.S., Heagerty P.J., and Kowdley K.V. Racial differences in the relationship between hepatitis C infection and iron stores. Hepatology 37 (2003) 795-801
33. Gandon Y., Olivie D., Guyader D., Aube C., Oberti F., Sebille V., et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet 363 (2004) 357-362
34. Di Bisceglie A.M., Bonkovsky H.L., Chopra S., Flamm S., Reddy R.K., Grace N., et al. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. Hepatology 32 (2000) 135-138
35. Facchini F.S., Hua N.W., and Stoohs R.A. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 122 (2002) 931-939